BioSpace News Archive

Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to cell therapy and outline upcoming clinical development plans at the 38th Annual J.P. Morgan Healthcare Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), announced today that the principal investigator of the Company’s Phase II liver cancer study, Dr. Solomon Stemmer, will deliver a presentation titled “The Safety and Efficacy of Namodenoson in the Second-Line Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients with Underlying Child-Pugh B (CPB) Liver Cirrhosis:

Purchases Over $350,000 of New Computer Numerical Control Machines and Fabrication Equipment

Partnership will enable expansion of proprietary vision correction platform into new therapeutic, diagnostic and telehealth applications

Medvantx, Inc., the leading provider of ecommerce and final mile delivery solutions, announces that Jeremy V. Gross has joined the company as Chief Technology Officer.

Cerner Corporation, a global health care technology company, announced that Brent Shafer, chairman and CEO, Donald Trigg, executive vice president of Strategic Growth and Marc Naughton, chief financial officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Potential breakthrough therapies for Huntington’s, Alzheimer’s, ALS and Parkinson’s among numerous programs advancing in the clinic

After Scaling 15-fold in the Last 3 Years and Crossing 20,000 Devices Shipped, New Funding Will Aid Further Growth and Entry into the US Market

As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced the acquisition of Impopharma Canada Limited with operations in Ontario, Canada.

Cancer Research UK to fund exploratory development of BT7401 through a Phase IIa clinical study